Abstract: The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.
Type:
Grant
Filed:
October 5, 2010
Date of Patent:
November 6, 2012
Assignees:
Bristol-Myers Squibb Company, Lexicon Pharmaceuticals, Inc.
Inventors:
Carolyn Diane Dzierba, Richard A. Hartz, Yingzhi Bi, Vijay T. Ahuja, Joanne J. Bronson, Kenneth Carson, Giovanni Cianchetta, Michael Green, David Kimball, S. Roy Kimura, Soojin Kwon, John E. Macor, Yulian Zhang, Greg Zipp
Abstract: Methods of synthesizing sodium glucose co-transporter 2 inhibitors, as well as compounds useful therein, are disclosed. Particular inhibitors are compounds of formula I.
Type:
Grant
Filed:
August 11, 2011
Date of Patent:
October 23, 2012
Assignee:
Lexicon Pharmaceuticals, Inc.
Inventors:
Nicole Cathleen Goodwin, Bryce Alden Harrison, Shinya Iimura, Ross Mabon, Qiuling Song, Wenxue Wu, Jie Yan, Haiming Zhang, Matthew Mangzhu Zhao
Abstract: Solid forms of anhydrous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol are disclosed, in addition to methods of their use in the treatment of various diseases and disorders.
Type:
Grant
Filed:
July 15, 2009
Date of Patent:
July 10, 2012
Assignee:
Lexicon Pharmaceuticals, Inc.
Inventors:
Susan Margaret De Paul, Anett Perlberg, Matthew Mangzhu Zhao
Abstract: Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.
Type:
Application
Filed:
December 8, 2011
Publication date:
July 5, 2012
Applicant:
LEXICON PHARMACEUTICALS, INC.
Inventors:
E-Chiang Lee, Gregory M. Landes, Kyu Chung, Ling Chen, Urvi Desai, David Reed Powell, Seokjoo Hong
Abstract: Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate and salts thereof are disclosed.
Type:
Grant
Filed:
September 25, 2008
Date of Patent:
June 5, 2012
Assignee:
Lexicon Pharmaceuticals, Inc.
Inventors:
Mark S. Bednarz, Susan De Paul, Ramanaiah C. Kanamarlapudi, Anett Perlberg, Haiming Zhang
Abstract: Inhibitors of LIM kinase 2 are disclosed, along with pharmaceutical compositions comprising them and methods of their use.
Type:
Grant
Filed:
April 20, 2009
Date of Patent:
June 5, 2012
Assignee:
Lexicon Pharmaceuticals, Inc.
Inventors:
Hugh Alfred Burgoon, Nicole Cathleen Goodwin, Bryce Alden Harrison, Jason Patrick Healy, Ying Liu, Ross Mabon, Brett Marinelli, David Brent Rawlins, Dennis Stewart Rice, Norris Andrew Whitlock
Abstract: Aryl pyridines, compositions comprising them, and methods of their use for the treatment, prevention and management of a variety of diseases and disorders are disclosed.
Type:
Grant
Filed:
July 31, 2006
Date of Patent:
April 10, 2012
Assignee:
Lexicon Pharmaceuticals, Inc.
Inventors:
David J. Augeri, James E. Tarver, Jr., Qinghong Fu, Michael Victor Voronkov, Doan Hackley, Michael E. Mertzman, Marianne Carlsen
Abstract: Imidazole-based compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of inflammatory and autoimmune diseases and disorders are disclosed.
Type:
Grant
Filed:
December 1, 2009
Date of Patent:
January 10, 2012
Assignee:
Lexicon Pharmaceuticals, Inc.
Inventors:
David J. Augeri, Jeffrey Bagdanoff, Lakmal W. Boteju, Kenneth G. Carson, Theodore C. Jessop, Spencer David Kimball
Abstract: O-linked pyrimidin-4-amine-based compounds, pharmaceutical compositions comprising them, and methods of their use are described.
Type:
Grant
Filed:
December 12, 2007
Date of Patent:
January 10, 2012
Assignee:
Lexicon Pharmaceuticals, Inc.
Inventors:
David J. Augeri, Marianne Carlsen, Kenneth G. Carson, Qinghong Fu, Jason P. Healy, Alexander Heim-Riether, Theodore C. Jessop, Philip E. Keyes, Min Shen, James E. Tarver, Jerry A. Taylor, Xiaolian Xu
Abstract: Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.
Type:
Grant
Filed:
December 4, 2009
Date of Patent:
January 10, 2012
Assignee:
Lexicon Pharmaceuticals, Inc.
Inventors:
E-Chiang Lee, Gregory M. Landes, Kyu Chung, Ling Chen, Urvi Desai, David Reed Powell, Seokjoo Hong
Abstract: Methods and compositions comprising tryptophan hydroxylase inhibitors are disclosed. Particular methods are directed at reducing or avoiding serotonin-mediated adverse effects associated with some drugs.
Abstract: 4-Amino-1H-pyrimidin-2-one-based compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of various diseases and disorders are disclosed.
Type:
Grant
Filed:
December 12, 2007
Date of Patent:
January 10, 2012
Assignee:
Lexicon Pharmaceuticals, Inc.
Inventors:
David J. Augeri, Marianne Carlsen, Kenneth G. Carson, Qinghong Fu, Alexander Heim-Riether, Theodore C. Jessop, James E. Tarver, Jerry A. Taylor
Abstract: Compounds of formulae I and II are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and manage serotonin-mediated diseases and disorders:
Abstract: Monoclonal antibodies that specifically bind to ANGPTL3 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL3 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.
Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO57290 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as cardiovascular, endothelial or angiogenic disorders; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; or developmental abnormalities.
Abstract: Solid forms of (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol and hydrates thereof are disclosed, as well as compositions comprising them and methods of their use.
Type:
Grant
Filed:
June 16, 2009
Date of Patent:
August 16, 2011
Assignee:
Lexicon Pharmaceuticals, Inc.
Inventors:
Hugh Alfred Burgoon, Suzanne Marie Buttar, Christopher Stephen Frampton